• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在接受基于伊沙佐米治疗的复发/难治性多发性骨髓瘤患者中（AGMT MM 1，II期试验），口腔微生物群的α多样性降低与无进展生存期缩短相关。

Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial).

作者信息

Ludwig Heinz, Hausmann Bela, Schreder Martin, Pönisch Wolfram, Zojer Niklas, Knop Stefan, Gunsilius Eberhard, Egle Alexander, Petzer Andreas, Einsele Hermann, Hajek Roman, Weisel Katja, Krenosz Karl Jochen, Lang Alois, Lechner Daniel, Greil Richard, Berry David

机构信息

Wilhelminen Cancer Research Institute Vienna Austria.

Joint Microbiome Facility (JMF) Medical University of Vienna & University of Vienna Vienna Austria.

出版信息

EJHaem. 2020 Nov 8;2(1):99-103. doi: 10.1002/jha2.130. eCollection 2021 Feb.

DOI:10.1002/jha2.130
PMID:35846090
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9176146/
Abstract

Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib-thalidomide-dexamethasone. Increased alpha diversity (Shannon index) at the phylum level was associated with longer progression-free survival (PFS) (10.2 vs 8.5 months,  = .04), particularly in patients with very long (>75% quartile) PFS . Additionally, alpha diversity was lower in patients with progressive disease ( < .05). These findings suggest an interrelationship between the oral microbiome and outcome in patients with MM and encourage a novel direction for diagnostic and/or therapeutic strategies.

摘要

人类微生物组的改变已与多种恶性疾病相关联。在此，我们调查了79例接受伊沙佐米-沙利度胺-地塞米松治疗的复发/难治性多发性骨髓瘤（MM）患者的口腔微生物组。门水平上α多样性（香农指数）增加与更长的无进展生存期（PFS）相关（10.2个月对8.5个月，P = 0.04），特别是在PFS非常长（>四分位数75%）的患者中。此外，疾病进展患者的α多样性较低（P < 0.05）。这些发现表明MM患者口腔微生物组与预后之间存在相互关系，并为诊断和/或治疗策略开辟了新方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a9a/9176146/255a91976736/JHA2-2-99-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a9a/9176146/59125be92231/JHA2-2-99-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a9a/9176146/255a91976736/JHA2-2-99-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a9a/9176146/59125be92231/JHA2-2-99-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a9a/9176146/255a91976736/JHA2-2-99-g002.jpg

相似文献

1
Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial).在接受基于伊沙佐米治疗的复发/难治性多发性骨髓瘤患者中（AGMT MM 1，II期试验），口腔微生物群的α多样性降低与无进展生存期缩短相关。
EJHaem. 2020 Nov 8;2(1):99-103. doi: 10.1002/jha2.130. eCollection 2021 Feb.
2
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.MUK8 方案：一项随机 II 期临床试验，评估环磷酰胺和地塞米松联合伊沙佐米治疗来那度胺、(lenalidomide)和蛋白酶体抑制剂治疗后复发的复发/难治性多发性骨髓瘤（RRMM）患者的疗效。
Trials. 2020 Oct 2;21(1):826. doi: 10.1186/s13063-020-04739-8.
3
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.随机、双盲、安慰剂对照的 III 期研究，评估伊沙佐米联合来那度胺-地塞米松治疗复发/难治性多发性骨髓瘤患者：中国延续研究。
J Hematol Oncol. 2017 Jul 6;10(1):137. doi: 10.1186/s13045-017-0501-4.
4
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.来那度胺、伊沙佐米和地塞米松联合治疗多发性骨髓瘤。
N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.
5
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.基于伊沙佐米的方案治疗复发/难治性多发性骨髓瘤：真实世界数据与临床试验结果是否一致？一项多中心以色列登记研究。
Ann Hematol. 2020 Jun;99(6):1273-1281. doi: 10.1007/s00277-020-03985-9. Epub 2020 Mar 20.
6
[Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime].口服伊沙佐米-来那度胺-地塞米松方案用于复发难治性多发性骨髓瘤的长期无进展生存
Orv Hetil. 2021 Sep 5;162(36):1451-1458. doi: 10.1556/650.2021.32179.
7
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.在 TOURMALINE-MM1 研究中，先前治疗对复发/难治性多发性骨髓瘤患者口服伊沙佐米-来那度胺-地塞米松与安慰剂-来那度胺-地塞米松的疗效和安全性的影响。
Haematologica. 2017 Oct;102(10):1767-1775. doi: 10.3324/haematol.2017.170118. Epub 2017 Jul 27.
8
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.在常规临床实践中，来那度胺和地塞米松（Rd）与伊沙佐米、来那度胺和地塞米松（IRD）相比，对复发和难治性多发性骨髓瘤患者的生存获益。
BMC Cancer. 2021 Jan 15;21(1):73. doi: 10.1186/s12885-020-07732-1.
9
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.来那度胺-地塞米松联合伊沙佐米诱导治疗后序贯伊沙佐米维持治疗复发/难治性多发性骨髓瘤患者的研究
Br J Cancer. 2019 Oct;121(9):751-757. doi: 10.1038/s41416-019-0581-8. Epub 2019 Sep 27.
10
A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial.一项关于伊沙佐米、沙利度胺和地塞米松连续治疗复发和/或难治性多发性骨髓瘤的 II 期临床试验：澳大利亚骨髓瘤研究联盟（AMaRC）16-02 试验。
Br J Haematol. 2021 Aug;194(3):580-586. doi: 10.1111/bjh.17504. Epub 2021 May 15.

引用本文的文献

1
Impact of Chemotherapy Alone and in Combination with Immunotherapy on Oral Microbiota in Cancer Patients-A Pilot Study.单纯化疗及联合免疫疗法对癌症患者口腔微生物群的影响——一项初步研究
Microorganisms. 2025 Jul 3;13(7):1565. doi: 10.3390/microorganisms13071565.
2
Changes in Oral Microbial Diversity in a Piglet Model of Traumatic Brain Injury.创伤性脑损伤仔猪模型口腔微生物多样性的变化
Brain Sci. 2022 Aug 21;12(8):1111. doi: 10.3390/brainsci12081111.
3
Analysis of microbiome in gastrointestinal stromal tumors: Looking for different players in tumorigenesis and novel therapeutic options.

本文引用的文献

1
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation.肠道菌群作为异基因造血细胞移植患者死亡的预测因子。
N Engl J Med. 2020 Feb 27;382(9):822-834. doi: 10.1056/NEJMoa1900623.
2
Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing.基于定量聚合酶链反应（QPCR）和 16S rRNA 高通量测序分析中国多发性骨髓瘤患者粪便微生物分类群变化。
Med Sci Monit. 2019 Nov 3;25:8269-8280. doi: 10.12659/MSM.919988.
3
Oral-Gut Microbiota and Arthritis: Is There an Evidence-Based Axis?
胃肠道间质瘤的微生物组分析：寻找肿瘤发生中的不同参与者和新的治疗选择。
Cancer Sci. 2022 Aug;113(8):2590-2599. doi: 10.1111/cas.15441. Epub 2022 Jun 21.
4
Flavin-Containing Monooxygenase 3 (FMO3) Is Critical for Dioxin-Induced Reorganization of the Gut Microbiome and Host Insulin Sensitivity.含黄素单加氧酶3（FMO3）对二噁英诱导的肠道微生物群重组和宿主胰岛素敏感性至关重要。
Metabolites. 2022 Apr 18;12(4):364. doi: 10.3390/metabo12040364.
口腔-肠道微生物群与关节炎：是否存在循证轴？
J Clin Med. 2019 Oct 22;8(10):0. doi: 10.3390/jcm8101753.
4
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.来那度胺-地塞米松联合伊沙佐米诱导治疗后序贯伊沙佐米维持治疗复发/难治性多发性骨髓瘤患者的研究
Br J Cancer. 2019 Oct;121(9):751-757. doi: 10.1038/s41416-019-0581-8. Epub 2019 Sep 27.
5
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition.多发性骨髓瘤微小残留病灶阴性与肠道微生物组成有关。
Blood Adv. 2019 Jul 9;3(13):2040-2044. doi: 10.1182/bloodadvances.2019032276.
6
Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression.微生物群驱动的白细胞介素-17 产生细胞和嗜酸性粒细胞协同作用加速多发性骨髓瘤的进展。
Nat Commun. 2018 Dec 3;9(1):4832. doi: 10.1038/s41467-018-07305-8.
7
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.肠道微生物群调节黑色素瘤患者对抗PD-1免疫疗法的反应。
Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.
8
Stress and stability: applying the Anna Karenina principle to animal microbiomes.压力与稳定：应用《安娜·卡列尼娜》原则于动物微生物组。
Nat Microbiol. 2017 Aug 24;2:17121. doi: 10.1038/nmicrobiol.2017.121.
9
DADA2: High-resolution sample inference from Illumina amplicon data.DADA2：从Illumina扩增子数据进行高分辨率样本推断。
Nat Methods. 2016 Jul;13(7):581-3. doi: 10.1038/nmeth.3869. Epub 2016 May 23.
10
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection.治疗前肠道微生物群可预测化疗相关的血流感染。
Genome Med. 2016 Apr 28;8(1):49. doi: 10.1186/s13073-016-0301-4.